The Community Resource in Targeted Therapies
Driving Knowledge. Empowering Change. Optimizing Outcomes.
ONCAlert | Upfront Therapy for mRCC

Comparing Toxicities and Patient-Stated Preference in the SWOG S0307 Trial

Julie R. Gralow, MD
Published Online: 9:46 PM, Mon June 2, 2014
Julie R. Gralow, MD, director, Breast Medical Oncology, Seattle Cancer Care Alliance, discusses an analysis of the phase III SWOG S0307 trial comparing toxicities and patient-stated preference for oral versus intravenous delivery of bisphosphonates as adjuvant therapy in primary breast cancer.

<<< Back to the ASCO 2014 conference page
 



Copyright © TargetedOnc 2018 Intellisphere, LLC. All Rights Reserved.